ENDONOVO THERAPEUTICS, INC. Income Statement
ENDV|9 years of annual SEC 10-K data (FY2011-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
ENDONOVO THERAPEUTICS, INC. reported $135,355 in revenue and $18M in net loss for FY2022. Revenue has grown at a 10.4% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $135.4K | $73.1K | $165.8K | $310.2K | $83.3K | - | $4.3K | $24.2K | $45.5K |
| Cost of Revenue | $10.0K | $15.0K | $65.4K | $93.4K | $12.9K | - | $2.2K | $15.5K | - |
| Gross Profit | $125.4K | $58.1K | $100.4K | $216.8K | $70.3K | - | $2.1K | $8.7K | - |
| R&D Expense | - | $0 | $3.3K | $153.1K | $274.3K | $0 | - | - | - |
| Operating Income | -$3.3M | -$2.2M | -$2.9M | -$3.8M | -$4.2M | -$5.4M | -$2.6M | -$2.2M | -$95.5K |
| Interest Expense | - | $941.6K | $2.1M | $17.0K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | $0 | $800 |
| Net Income | -$18.5M | -$3.1M | -$395.6K | -$17.3M | -$6.4M | -$5.3M | -$6.8M | -$959.5K | -$94.1K |
| EPS (Basic) | -$0.05 | - | - | - | - | - | - | - | - |
| EPS (Diluted) | - | -$0.03 | -$24.83 | -$17.76 | -$0.04 | -$0.07 | -$0.03 | -$3.96 | -$0.02 |
| Shares Outstanding | 74.5M | 24.5M | 1.2M | 431.1K | 317.0M | 104.8M | 81.4M | 832.2K | - |
| Gross Margin | 92.6% | 79.5% | 60.6% | 69.9% | 84.5% | - | 49.3% | 36.0% | - |
| Operating Margin | -2411.7% | -3045.7% | -1756.5% | -1228.1% | -4995.3% | - | -60132.7% | -9057.6% | -209.7% |
| Profit Margin | -13649.2% | -4247.2% | -238.6% | -5582.4% | -7729.5% | - | -158633.9% | -3966.2% | -206.6% |